Coesisting inflammatory skin diseases: Tildrakizumab to control psoriasis and omalizumab for urticaria.
chronic spontaneous urticaria
dual biologic therapy
omalizumab
psoriasis
tildrakizumab
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
24
12
2021
received:
25
11
2021
accepted:
03
02
2022
pubmed:
10
2
2022
medline:
7
4
2022
entrez:
9
2
2022
Statut:
ppublish
Résumé
In Western countries, the number of individuals suffering from an autoimmune condition is constantly growing and often patients suffering from autoimmune disease are susceptible to developing a second autoimmune disorder. We report a case of an adult female patient affected by psoriasis vulgaris and treated with tildrakizumab, a humanized monoclonal antibody targeting interleukin-23, who later developed chronic spontaneous urticaria and started omalizumab, a humanized antibody to IgE, showing a favorable outcome. We speculate that the two combined therapies have restored the cytokine balance bringing it toward tolerance and remission of the two pathologies. It is conceivable that tildrakizumab may have a synergic action with omalizumab in the treatment of urticaria in patients affected by both psoriasis and urticaria. Our case and the study of the mechanisms of action of the two drugs suggest how the two therapies can act with an interlocking mechanism in achieving the final therapeutic effect.
Substances chimiques
Anti-Allergic Agents
0
Antibodies, Monoclonal, Humanized
0
Omalizumab
2P471X1Z11
tildrakizumab
DEW6X41BEK
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15359Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Banaszczyk K. Tildrakizumab in the treatment of psoriasis - literature review. Reumatologia. 2019;57(4):234-238. doi:10.5114/reum.2019.87620
Kumar B, Jain R, Sandhu K, Kaur I, Handa S. Epidemiology of childhood psoriasis: a study of 419 patients from northern India. Int J Dermatol. 2004;43(9):654-658.
Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy ClinImmunol. 1989;84(1):66-71.
Kolkhir P, Borzova E, Grattan C, Asero R, Pogorelov D, Maurer M. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. Autoimmun Rev. 2017;16(12):1196-1208.
Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):854-862. doi:10.1111/bjd.16083
Diluvio L, Vollono L, Zangrilli A, et al. Omalizumab and adalimumab: a winning couple. Immunotherapy. 2020;12(18):1287-1292. doi:10.2217/imt-2020-0203
Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72:519-533.
Türk M, Carneiro-Leão L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to treat patients with chronic spontaneous Urticaria with Omalizumab: questions and answers. J Allergy ClinImmunol Pract. 2020;8(1):113-124.
Kimball AB, Papp KA, Reich K, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. Br J Dermatol. 2020;182(6):1359-1368. doi:10.1111/bjd.18484
Toubi E, Vadasz Z. The emerging role of IL-17 in the immune-pathogenesis of chronic spontaneous urticaria. Immunotargets Ther. 2020;22(9):217-223.
Sabag DA, Matanes L, Bejar J, et al. Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy. 2020;50(7):799-804.
Leung S, Liu X, Fang L, Chen X, Guo T, Zhang J. The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol. 2010;7:182-189. doi:10.1038/cmi.2010.22
Atwa MA, Emara AS, Youssef N, Bayoumy NM. Serum concentration of IL-17, IL-23 and TNF-α among patients with chronic spontaneous urticaria: association with disease activity and autologous serum skin test. J Eur Acad Dermatol Venereol. 2014;28(4):469-474. doi:10.1111/jdv.12124
Abdel-Gadir A, Schneider L, Casini A, et al. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018;48(7):825-836.